Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms

Kampa-Schittenhelm, Kerstin Maria; Heinrich, Michael Charles; Akmut, Figen; Döhner, Hartmut; Doehner, Konstanze; Schittenhelm, Marcus Matthias

Erstveröffentlichung

2013

Metadata only
Search for full text

Wissenschaftlicher Artikel

Autoren

Kampa-Schittenhelm, Kerstin Maria

Heinrich, Michael Charles

Akmut, Figen

Döhner, Hartmut

Doehner, Konstanze

et al.

Institutionen

UKU. Klinik für Innere Medizin III

Erschienen in

Molecular cancer ; 12 (2013). - Art.-Nr. 19. - ISSN 1476-4598

Link zur Veröffentlichung

https://dx.doi.org/10.1186/1476-4598-12-19

Förderinformationen

Deutsche Krebshilfe Foundation
IZKF Program of the Medical Faculty Tubingen
Carreras Scholarship Program
Leukemia and Lymphoma Society
Department of Veterans Affairs
etc.

Schlagwörter

AC220; Quizartinib; Leukemia; KIT; FLT3; PDGFR; acute myeloid-leukemia; gastrointestinal stromal tumor; internal tandem duplications; ligand-independent activation; mast-cell leukemia; c-kit; myelodysplastic syndrome; flt3 gene; wild-type; systemic mastocytosis

DDC-Sachgruppe

DDC 610 / Medicine & health

Metadata

Zur Langanzeige